Monitor the annual meeting on May 21 for any dissident proposals or changes in board composition. The appointment may reduce activist pressure, but the proxy fight context remains active—watch for further filings or investor communications.
Price Chart
Executive Summary
Actuate Therapeutics filed a proxy supplement disclosing the appointment of Dr. Martin H. Huber as an independent director, expanding the board from 7 to 8 members. This adds depth to the board with a seasoned biopharma executive, but the timing near a proxy fight suggests it may be a response to activist pressure. No material financial impact, but the move could influence the upcoming May 21 annual meeting vote.
Key Financial Metrics
Key Facts
- Board expanded from 7 to 8 directors; Dr. Huber appointed effective May 1, 2026.
- Dr. Huber is an independent director with extensive executive and clinical experience (ex-CEO of Mersana, ex-CMO of TESARO, ex-VP at Merck).
- He received an initial grant of 30,000 stock options (3-year vest) and an annual retainer of $44,000.
- Additional consulting agreement provides quarterly fee of $3,000 for R&D advisory services.
- The supplement is in connection with the 2026 Annual Meeting scheduled for May 21, 2026.
Financial Impact
No material financial impact; compensation is standard non-employee director program.
Risk Factors
- Potential for ongoing proxy contest if activist demands are not fully addressed.
- New director's influence on R&D strategy could shift pipeline priorities.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001683168-26-003517 |
| Document: 0001683168-26-003517-index-headers.html | 0001683168-26-003517 |
| Document: 0001683168-26-003517-index.html | 0001683168-26-003517 |
| Document: 0001683168-26-003517.txt | 0001683168-26-003517 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $0.3548 | awaiting T+5 | — | $0.5280 (−48.82%) |
Oct 27, 2026 today | EFFECT | $0.5200 | awaiting T+5 | — | $0.5280 (−1.54%) |
Oct 19, 2026 8d ago | S-1/A | $0.5990 $0.5279 | ▲ +11.87% | ▲ +11.72% | $0.5280 (+11.85%) |
Oct 14, 2026 13d ago | S-1/A | $0.4342 $0.5622 | ▼ −29.48% | ▼ −29.03% | $0.5280 (−21.60%) |
Oct 6, 2026 20d ago | S-1 | $0.7240 $0.4340 | ▲ +40.06% | ▲ +39.07% | $0.5280 (+27.07%) |
Aug 12, 2026 10w ago | Institutional Cluster | $0.9699 $1.06 | ▼ −9.29% | ▼ −9.73% | $0.5280 (+45.56%) |
Jun 9, 2026 20w ago | Press Release | $2.01 $2.05 | ▲ +1.99% | ▼ −0.42% | $0.5280 (−73.73%) |
May 11, 2026 24w ago | 8-K | $2.89 $2.43 | ▼ −15.92% | ▼ −15.99% | $0.5280 (−81.73%) |
May 6, 2026 24w ago | DEFA14A | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.5280 (−82.34%) |
May 6, 2026 24w ago | 8-K | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.5280 (−82.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers